Prediction of minimal residual disease in pediatric ALL: Comparison and evaluation of different mathematical methods applied to data from the ALL-BFM 2000 trial

In pediatric acute lymphoblastic leukemia (ALL), the most important prognostic factor for the risk of relapse is the evaluation of minimal residual disease (MRD) at defined timepoints. The results of MRD analyses are not available at diagnosis to guide selection of the optimal treatment intensity already early on.